title: Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.
abstract: Widespread antimonial resistance in anthroponotic visceral leishmaniasis (VL) makes it critical to monitor the susceptibility of prevailing field isolates to upcoming antileishmanials in order to frame the right treatment policies to protect these drugs against development of resistance. We aimed to generate the baseline data on natural in vitro susceptibility to paromomycin and sitamaquine in Leishmania donovani field isolates from VL patients (n = 20) coming from zones of varying sodium antimony gluconate (SAG) resistance. We further monitored nitric oxide (NO) release in infected macrophages treated with these drugs. Field isolates exhibited variable sensitivity to paromomycin and sitamaquine with respective mean 50% effective dose (ED₅₀) values ± standard error of the mean (SEM) of 3.9 ± 0.3 μM and 2.1 ± 0.2 μM at the intracellular amastigote stage and 29.8 ± 2.5 μM and 17.7 ± 1.0 μM at the promastigote stage. Susceptibilities at the two parasite stages did not correlate for either drug. Isolates from high SAG resistance zones exhibited significantly lower susceptibility to sitamaquine than those from low SAG resistance zones, while isolates from different zones showed similar susceptibilities to paromomycin. NO release was promoted in L. donovani-infected macrophages upon treatment with paromomycin/sitamaquine. NO inhibitors significantly compromised amastigote killing by sitamaquine, but not by paromomycin. In conclusion, SAG-resistant/sensitive VL isolates were susceptible to both paromomycin and sitamaquine. Paromomycin, exhibiting higher efficacy against SAG-resistant parasites and having a distinct mechanism of action, appears to be a promising drug for combination therapy.
authors.affiliation: Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi 110029, India.
authors.forename: Arpita
authors.initials: A
authors.lastname: Kulshrestha
authors.forename: Ruchi
authors.initials: R
authors.lastname: Singh
authors.forename: Dhiraj
authors.initials: D
authors.lastname: Kumar
authors.forename: Narender Singh
authors.initials: NS
authors.lastname: Negi
authors.forename: Poonam
authors.initials: P
authors.lastname: Salotra
mesh_terms: D000634:Aminoquinolines / Q000494:pharmacology*; D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D004351:Drug Resistance; D006801:Humans; D007893:Leishmania donovani / Q000187:drug effects*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D009569:Nitric Oxide / Q000096:biosynthesis; D010303:Paromomycin / Q000494:pharmacology*
chemical_list: D000634:Aminoquinolines; D000981:Antiprotozoal Agents; D009569:Nitric Oxide; D010303:Paromomycin; C080436:8-aminoquinoline